Seeking Alpha

Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell ...

- Ongoing clinical trial is the first ever to combine targeted radiotherapy conditioning, Iomab-ACT, with CAR-T cell therapy to achieve lymphodepletion along with reduction of cytokine release ...
Nasdaq

InnerScope Hearing (OTC: INND) Signs an LOI to License Audio Cardio Inc. Sound Therapy Tech to Deploy a Subscription-Based App

Inner Scope plans to develop and market a subscription-based mobile app using AudioCardio's proprietary clinically proven Threshold Sound Conditioning Technology for the 188+ million people who own a ...
Nasdaq

Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy

NEW YORK, March 24, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its collaborator, Memorial Sloan Kettering Cancer ...
Odessa American

Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at ...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more ...
Business Wire

Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting

-- Poster presentation of MGTA-145 investigator-initiated Phase 2 clinical trial data confirmed previously reported positive topline clinical data for stem cell mobilization and transplant in multiple ...
Healio

Gene therapy for sickle cell disease shows curative potential

Please provide your email address to receive an email when new articles are posted on . Three patients with sickle cell disease who received the investigational gene therapy ARU-1801 achieved and ...